Dimerix Bilan de santé

Santé financière contrôle des critères 6/6

Dimerix possède un total de capitaux propres de A$18.2M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$32.1M et de A$13.9M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$22.14m
Fonds propres	AU$18.19m
Total du passif	AU$13.89m
Total des actifs	AU$32.08m

Mises à jour récentes de la santé financière

Recent updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Jul 05

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Feb 17

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de DXB ( A$31.9M ) dépassent ses passifs à court terme ( A$3.4M ).

Passif à long terme: Les actifs à court terme de DXB ( A$31.9M ) dépassent ses passifs à long terme ( A$10.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: DXB est sans dette.

Réduire la dette: DXB n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: DXB dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: DXB dispose d'une marge de trésorerie suffisante pour 2.3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 15.6 % chaque année.

Dimerix Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Is Dimerix (ASX:DXB) Using Too Much Debt?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Recent updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Non Executive Director exercised options to buy AU$70k worth of stock.

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines